LEADERSHIP

Louis Ferrari, President and Chief Executive Officer, joined us in February, 2011.  Prior to joining us, Mr. Ferrari served as Vice President of Oncology and Nephrology, Sales and Marketing at Centocor Ortho-Biotech where he was responsible for Procrit and Doxil and the impending launch of Abiraterone for Chemotherapy Resistant Metastatic Prostate Cancer.  Mr. Ferrari served on the board of Directors for both Ortho Biotech and Centocor Ortho Biotech from 2004 to 2011.  He also served as Vice President of Clinical Affairs and Executive Director of Clinical Affairs at Ortho-Biotech.   Mr. Ferrari brings over 30 years of experience in the pharmaceutical industry, including expertise in product launches, new product development, international marketing, sales management, sales training, licensing and acquisitions and clinical trials.  During that time, he held senior management positions of increasing responsibilities at Johnson and Johnson, Oxford GlycoSciences, Ortho-McNeil Pharmaceutical and Eli Lilly.  He earned his Bachelor of Science in Pharmacy from the Brooklyn College of Pharmacy and a Masters of Business Administration from Adelphi University.

Richard Crowley joined us in April, 2011 as Executive Vice President of Biopharmaceutical Operations and was named Chief Operating Officer in April, 2013. Prior to joining Savient, Mr. Crowley served as Senior Vice President, Biopharmaceutical Operations at ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company. In that role, he was responsible for the clinical and commercial manufacturing of ImClone's products along with Process and Analytical Development, Engineering, Facilities, Logistics and Validation. Mr. Crowley started at ImClone in 2000 with the mission to create and run the manufacturing organization required for the commercialization of Erbitux and the support of the development of the clinical pipeline. Prior to joining ImClone, he held several management-level positions at BASF Bioresearch Corp and held technical positions at Genencor International, Eastman Kodak Company and Monsanto. Mr. Crowley earned a Bachelor of Science degree in Chemistry from Denison University and a Master's of Science in Engineering in the area of chemical engineering from the University of Pennsylvania.

Kenneth M. Bahrt, M.D. joined us in August, 2011 as Senior Vice President and Chief Medical Officer.  Dr. Bahrt, a Board Certified Rheumatologist, brings to Savient over 25 years of global medical affairs, drug safety and clinical practice, research and life-cycle management experience in the pharmaceutical industry.  Dr. Bahrt is responsible for the overall management of Savient’s clinical development, drug safety and medical affairs teams.  Prior to joining Savient, Dr. Bahrt served as Therapeutic Area Head for US Medical Affairs (Immunology) at Genentech, leading the medical affairs team for four marketed biological products and serving as the US medical lead on their Rheumatology Global Franchise Team.  He previously served as Global Medical Director (Inflammation and Immunology) for F. Hoffmann - La Roche, Inc.  Dr. Bahrt also worked in leadership positions at Bristol-Myers Squibb Co., where he was the Executive Director of Global Medical Affairs (Immunology), and Pfizer, where he served as Medical Director and Team Leader for rheumatology portfolio products. Prior to joining the pharmaceutical industry, Dr. Bahrt had a rheumatology practice for 15 years. 

Stephen Davies, Senior Vice President and Chief Administrative Officer joined Savient in February, 2011. Mr. Davies has over 20 years of experience in developing and managing IT and business strategy for biotech companies and leads Savient's administrative functions including Human Resources, Information Technology and Facilities. Prior to joining us, Mr. Davies served as Vice President of Information Technology at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, where he was responsible for developing an IT strategy to enable international expansion, support clinical growth and improve infrastructure security. Prior to that, Mr. Davies served as Executive Director of Research, Development and Medical Systems at Boehringer Ingelheim Pharmaceuticals, Inc., and has also held positions at Revlon, Inc. and TIAA-CREF. He earned his Bachelor of Arts from Rowan State University.

John Hamill
Senior Vice President, Chief Financial Officer

John Hamill joined Savient in September 2012 as Senior Vice President and Chief Financial Officer. Mr. Hamill is responsible for all financial and accounting functions of the Company. Previously, Mr. Hamill served as Chief Financial Officer of PharmaNet Development Group, Inc., a leading global supplier of drug development services, and its wholly owned subsidiary PharmaNet, Inc., where he directed financial and administrative operations. Prior to that role, Mr. Hamill held senior financial management positions of increasing responsibility and breadth at Omnicare Clinical Research and financial management positions at Rhone-Poulenc, Freedom Chemical Company, International Paper and Johnson & Johnson. Mr. Hamill holds a Bachelor of Science in Accounting/Business and Computer Science from DeSales University, is a Certified Public Accountant and is a member of Pennsylvania and American Institutes of Certified Public Accountants.

Philip K. Yachmetz, our Senior Vice President, General Counsel and Secretary, joined us in May 2004 and served as our Chief Business Officer from February 2006 to November 2008. Mr. Yachmetz was Senior Vice President – Corporate Strategy, General Counsel and Secretary from May 2004 until February 2006. Mr. Yachmetz joined us from Progenics Pharmaceuticals, Inc., where he held the position of Vice President, General Counsel and Secretary from 2000 until 2004. From 1998 to 2000 he served as Senior Vice President, Business Development, General Counsel and Secretary at CytoTherapeutics, Inc. (now StemCells, Inc.). He also founded and served in 1997 to 1998 as Managing Director of Millennium Venture Management, LLC, a business consulting and advisory firm to the pharmaceutical, healthcare, and high technology industry. From 1989 to 1996, he held legal positions of increasing responsibility at Hoffmann-La Roche Inc. Mr. Yachmetz is an attorney admitted to the bar in New Jersey and New York.

David Veitch, President of Savient Pharma Ireland Limited, joined us in January 2012.  Prior to joining us, Mr. Veitch served as Senior Vice President of European Marketing & Brand Commercialization at Bristol-Myers Squibb where he was responsible for leading the brand commercial organization for Europe across all disease areas for the company.  Prior to serving in that role, Mr. Veitch spent ten years serving in a number of general management roles and other leadership positions at Bristol-Myers Squibb.  Before joining Bristol-Myers Squibb, Mr. Veitch spent ten years in a variety of managerial roles at SmithKline Beecham Pharmaceuticals.  Mr. Veitch brings over 24 years of international pharmaceutical industry experience and has extensive knowledge across many therapeutic areas including; Oncology, Virology, CV-Metabolism, CNS and Immunology. He received his Bachelor of Science degree from Bristol University in Bristol, England.